Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 10 mg, lactosum 80 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 15 mg, lactosum 120 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 20 mg, lactosum 160 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.2 mg, magnesii stearas, kapselhülle: gelatina, e 132, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - lenalidomidum - capsule rigide - lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.2 mg, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - onkologikum - synthetika

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

farmoz- sociedade tecnico medicinal, s.a. - bortezomib - bortezomib

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - busulfano - busulfano

Європейський Союз - італійська - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mieloma multiplo - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combinazione con bortezomib, talidomide e desametasone per il trattamento di pazienti adulti con nuova diagnosi di mieloma multiplo che sono eleggibili per il trapianto di cellule staminali autologhe. in combinazione con lenalidomide e desametasone, o bortezomib e desametasone per il trattamento di pazienti adulti con mieloma multiplo che hanno ricevuto almeno una precedente terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. come monoterapia per il trattamento di pazienti adulti con recidivo e refrattario mieloma multiplo, la cui prima terapia incluso un inibitore del proteasoma e un agente immunomodulante e che hanno dimostrato la progressione della malattia, l'ultima terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - busulfano - busulfano

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - busulfano - busulfano

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 5 mg, lactosum 147 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,4 mg, magnesio stearas, kapselhülle: gelatina, e-171, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika